雪榕生物
(300511)
| 流通市值：40.32亿 | | | 总市值：46.14亿 |
| 流通股本：5.60亿 | | | 总股本：6.41亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,324,930,751.78 | 790,674,852.9 | 440,692,931.37 | 2,162,449,367.04 |
| 营业收入 | 1,324,930,751.78 | 790,674,852.9 | 440,692,931.37 | 2,162,449,367.04 |
| 二、营业总成本 | 1,403,701,115.19 | 905,371,491.71 | 440,694,795.18 | 2,368,964,063.48 |
| 营业成本 | 1,226,720,606.52 | 780,898,014.04 | 374,560,312.56 | 2,084,497,171.57 |
| 税金及附加 | 14,899,124.42 | 9,709,019.65 | 4,770,388.17 | 20,290,577.71 |
| 销售费用 | 14,486,290.96 | 9,058,248.71 | 4,529,080.62 | 26,706,501 |
| 管理费用 | 100,594,021.39 | 69,759,574.61 | 35,523,181.47 | 139,068,237.46 |
| 研发费用 | 2,365,283.81 | 1,730,731.51 | 505,920.27 | 3,462,133.88 |
| 财务费用 | 44,635,788.09 | 34,215,903.19 | 20,805,912.09 | 94,939,441.86 |
| 其中:利息费用 | 44,644,101.28 | 34,518,017.55 | 19,104,464.69 | 98,207,748.29 |
| 其中:利息收入 | 266,688.17 | 149,839.5 | 77,642.78 | 2,472,980.16 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | -645,524.3 |
| 加:投资收益 | 1,013,061.49 | 1,013,061.49 | - | - |
| 资产处置收益 | 17,348,036.7 | 12,375,039.33 | 8,712,266.5 | 7,850,323.36 |
| 资产减值损失(新) | -1,058,136.82 | -662,693.74 | - | -419,434,378.42 |
| 信用减值损失(新) | -202,800.73 | 45,094.22 | -161,079.75 | -6,757,595.94 |
| 其他收益 | 8,088,972.65 | 5,550,218.46 | 3,450,029.09 | 11,681,732.88 |
| 四、营业利润 | -53,581,230.12 | -96,375,919.05 | 11,999,352.03 | -613,820,138.86 |
| 加:营业外收入 | 385,473.69 | 364,060.65 | 273,676.28 | 1,790,900.2 |
| 减:营业外支出 | 2,251,420.93 | 1,258,691.43 | 24,998.43 | 4,376,957.26 |
| 五、利润总额 | -55,447,177.36 | -97,270,549.83 | 12,248,029.88 | -616,406,195.92 |
| 减:所得税费用 | 759,982.62 | 3,046.03 | 5.63 | 66.28 |
| 六、净利润 | -56,207,159.98 | -97,273,595.86 | 12,248,024.25 | -616,406,262.2 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -56,207,159.98 | -97,273,595.86 | 12,248,024.25 | -616,406,262.2 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -62,348,351.93 | -102,552,021.15 | 7,242,399.82 | -617,070,813.21 |
| 少数股东损益 | 6,141,191.95 | 5,278,425.29 | 5,005,624.43 | 664,551.01 |
| 扣除非经常损益后的净利润 | -85,189,552.12 | -120,083,845.73 | -4,839,350.95 | -634,007,117.72 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.11 | -0.19 | 0.01 | -1.24 |
| (二)稀释每股收益 | -0.11 | -0.19 | 0.01 | -1.24 |
| 八、其他综合收益 | 764,947.24 | 741,303.82 | -61,046.09 | 1,653,157.21 |
| 归属于母公司股东的其他综合收益 | 431,503.3 | 428,555.07 | -50,838.5 | 996,197.65 |
| 九、综合收益总额 | -55,442,212.74 | -96,532,292.04 | 12,186,978.16 | -614,753,104.99 |
| 归属于母公司股东的综合收益总额 | -61,916,848.63 | -102,123,466.08 | 7,191,561.32 | -616,074,615.56 |
| 归属于少数股东的综合收益总额 | 6,474,635.89 | 5,591,174.04 | 4,995,416.84 | 1,321,510.57 |
| 公告日期 | 2025-10-16 | 2025-08-27 | 2025-04-28 | 2025-04-28 |
| 审计意见(境内) | | | | 标准无保留意见 |